Kostyrko, K., Román, M., Lee, A. G., Simpson, D. R., Dinh, P. T., Leung, S. G., Marini, K. D., Kelly, M. R., Broyde, J., Califano, A., Jackson, P. K., & Sweet-Cordero, E. A. (2023). UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39591-2

Paik, P. K., Luo, J., Ai, N., Kim, R., Ahn, L., Biswas, A., Coker, C., Ma, W., Wong, P., Buonocore, D. J., Lai, W. V., Chaft, J. E., Acharyya, S., Massagué, J., & Kris, M. G. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-33719-6

Henick, B. S., Villarroel-Espindola, F., Datar, I., Sanmamed, M. F., Yu, J., Desai, S., Li, A., Aguirre-Ducler, A., Syrigos, K., Rimm, D. L., Chen, L., Herbst, R. S., & Schalper, K. A. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 10(7), e005025. https://doi.org/10.1136/jitc-2022-005025